---
title: "The CRO concept sector has seen a surge, with BHC and HC CHEMICAL hitting the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233548039.md"
description: "The CRO concept sector has seen a rise, with BHC and HC CHEMICAL hitting the limit up, Nossar rising over 10%, and FuXiang Pharmaceutical, Hitec Bio, Hanyu Pharmaceutical, Ruizhi Pharmaceutical, and Haiyi Pharmaceutical also following suit"
datetime: "2025-03-28T02:01:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233548039.md)
  - [en](https://longbridge.com/en/news/233548039.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233548039.md)
generator: "portal-rs"
---

# The CRO concept sector has seen a surge, with BHC and HC CHEMICAL hitting the limit up

The CRO concept sector has seen a surge, with BHC and HC CHEMICAL hitting the daily limit, Nossan rising over 10%, and FuXiang Pharmaceutical, Hitec Bio, Hanyu Pharmaceutical, Ruizhi Pharmaceutical, and Haiyi Pharmaceutical also following suit

### Related Stocks

- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)
- [000953.CN](https://longbridge.com/en/quote/000953.CN.md)
- [301333.CN](https://longbridge.com/en/quote/301333.CN.md)
- [300497.CN](https://longbridge.com/en/quote/300497.CN.md)
- [300683.CN](https://longbridge.com/en/quote/300683.CN.md)
- [300199.CN](https://longbridge.com/en/quote/300199.CN.md)
- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)

## Related News & Research

- [Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea](https://longbridge.com/en/news/296784834.md)
- [GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability](https://longbridge.com/en/news/296439475.md)
- [GUBRA: Revenue fell sharply after last year's AbbVie deal, but pipeline and CRO growth continued](https://longbridge.com/en/news/296439393.md)
- [Cerro de Pasco Resources publishes FY2026 annual report](https://longbridge.com/en/news/296917802.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**